Issels Integrative Immuno-Oncology November 17, 2016  

Pancreatic Cancer: Hijacking the Immune System to Hide Its Growth

Dear Friend,

With a five-year survival rate of only three percent, pancreatic cancer is one of the more difficult types of cancer to treat. Scientists from Cancer Research UK, in collaboration with scientists from pharmaceutical giant AstraZeneca, recently announced their discovery of a promising method to help defeat these tumors.

Pancreatic Cancer's "Stealth Attack"

The immune system is your body's first line of defense against cancer cells and other foreign bodies that threaten your health. In the case of pancreatic cancer, once the cells make it past the initial gauntlet, they move on to hijack parts of the immune system to facilitate their growth.

The UK study, published in Cancer Cell, reported the team's discovery of CXCR2, which is a protein that serves as the gatekeeper for pancreatic tumors, guarding them from attack by immune cells. Use of an experimental drug that blocks CXCR2 allowed T-cells to enter the tumor, making it more vulnerable to treatment.

Immunotherapy for Pancreatic Cancer

Until now, the shielding process has made pancreatic cancer particularly resistant to immunotherapy. Professor Peter Johnson, chief clinician at Cancer Research UK, said their study suggests that using the new drug in concert with immunotherapy treatments could create "a powerful weapon" in the fight against pancreatic cancer.

Using the Body's Natural Defenses to Defeat Cancer

For more than 60 years, our Issels® center has been the leader in the use of immunotherapy for pancreatic cancer and many other types. Contact us today for more information about our personalized non-toxic treatments, including cancer vaccines, hyperthermia and gene-targeted therapies.

Pancreatic Cancer: Hijacking the Immune System to Hide Its Growth

Read more interesting articles on the "Issels Cancer Immunotherapy" news/blog posted every Tuesday and Thursday. Check It Out Now »


Hard to Fight Pancreatic Cancer Responds to Immunotherapy

Researchers at University of Rochester Medical Center in New York set out to find a treatment that could make pancreatic cancer more receptive to surgery. The test involved use of PF-0416309, an immunotherapy drug that targets immune cells in pancreatic tumors.

Get the Full Story!

Immunotherapy Could Be Key to Beating Pancreatic Cancer

According to the American Cancer Society estimates, pancreatic cancer is expected to kill an estimated 38,500 Americans this year. But hope may be on the horizon. An increasing body of research suggests that bacterial infections, particularly in the stomach and gums, play a significant role in the development of pancreatic cancer and may even act as a trigger for the disease.

Get the Full Story!

Videos – What Do Patients Say About Their Experience?

Watch videos of patients who share their own experiences at the Issels clinics with you. Listen to their stories and cancer journeys.

Get the Full Story!
Interested?

Learn More

Testimonials »

Treatments »

Vaccines »

Statistics »

History »

Locations »

Contact Us »

Connect With Us:


Google +

Contact Info:

Phone: 888-447-7357

Email: info@issels.com



Treatments | Testimonials | Contact Us